{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(9)"],"submitter":["Chen CT"],"pubmed_abstract":["<h4>Purpose</h4>In preclinical models, glucocorticoid receptor (GR) signaling drives resistance to taxane chemotherapy in multiple solid tumors via upregulation of antiapoptotic pathways. ORIC-101 is a potent and selective GR antagonist that was investigated in combination with taxane chemotherapy as an anticancer regimen preclinically and in a phase 1 clinical trial.<h4>Patients and methods</h4>The ability of ORIC-101 to reverse taxane resistance was assessed in cell lines and xenograft models, and a phase 1 study (NCT03928314) was conducted in patients with advanced solid tumors to determine the dose, safety, and antitumor activity of ORIC-101 with nab-paclitaxel.<h4>Results</h4>ORIC-101 reversed chemoprotection induced by glucocorticoids in vitro and achieved tumor regressions when comb"],"journal":["Cancer research communications"],"pagination":["2415-2426"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11396014"],"repository":["biostudies-literature"],"pubmed_title":["ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors."],"pmcid":["PMC11396014"],"pubmed_authors":["Hamilton E","Orr DW","Wang J","Barkund SR","Kummar S","Abdul-Karim RM","Davis SL","Khanna V","Patel MR","Chen CT","Ueno NT","Daemen A","Zhou H","Multani PS","Xu R","Sommerhalder D","Sun JD","Munster PN","Chow Maneval E","Jahchan NS","Junttila MR","Pankov A","Florou V","Duff M","Spira AI","Jauhari S","Jackson EL","Tolcher AW","Kong W"],"additional_accession":[]},"is_claimable":false,"name":"ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.","description":"<h4>Purpose</h4>In preclinical models, glucocorticoid receptor (GR) signaling drives resistance to taxane chemotherapy in multiple solid tumors via upregulation of antiapoptotic pathways. ORIC-101 is a potent and selective GR antagonist that was investigated in combination with taxane chemotherapy as an anticancer regimen preclinically and in a phase 1 clinical trial.<h4>Patients and methods</h4>The ability of ORIC-101 to reverse taxane resistance was assessed in cell lines and xenograft models, and a phase 1 study (NCT03928314) was conducted in patients with advanced solid tumors to determine the dose, safety, and antitumor activity of ORIC-101 with nab-paclitaxel.<h4>Results</h4>ORIC-101 reversed chemoprotection induced by glucocorticoids in vitro and achieved tumor regressions when comb","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-06-30T03:16:23.151Z","creation":"2025-04-04T11:04:10.124Z"},"accession":"S-EPMC11396014","cross_references":{"pubmed":["39177285"],"doi":["10.1158/2767-9764.CRC-24-0115"]}}